Compare Aurora Cannabis Inc (ACB) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

BRK.B trades at $500.02, down 1.32% today, with a bullish technical signal driven by moving averages. Analyst consensus is positive with 57% buy ratings. Key support lies at $499, while resistance is at $509. The stock's technical strength is supported by a high ADX indicating a strong trend.

The outlook for BRK.B is cautiously optimistic given strong analyst support and bullish technicals, but overbought RSI levels near 80 suggest potential near-term consolidation. Risks include market volatility and Berkshire Hathaway's exposure to economic cycles. Upside depends on continued earnings growth and strategic investments.